Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.

Authors :: Slyker JA
Casper C
Tapia K
Richardson B
Bunts L
Huang ML
Wamalwa D
Benki-Nugent S
John-Stewart G
Source :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2014 May; Vol. 58 (9), pp. 1333-7. Date of Electronic Publication: 2014 Feb 18.
Publication Year :: 2014
Abstract: We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan human immunodeficiency virus-infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest that specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies.

Subjects :: Drug Therapy, Combination
HIV Infections complications
Humans
Infant
Kenya
Lopinavir
Risk Factors
Anti-HIV Agents therapeutic use
Epstein-Barr Virus Infections prevention & control
HIV Infections drug therapy
Nevirapine therapeutic use
Ritonavir therapeutic use

Language :: English
ISSN :: 1537-6591
Volume :: 58
Issue :: 9
Database :: MEDLINE
Journal :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publication Type :: Academic Journal
Accession number :: 24550373
Full Text :: https://doi.org/10.1093/cid/ciu088

Full Text Access

Tools